

We Claim:

1. A vaccine comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle, wherein the nucleotide sequence is selected from SEQ ID No. 15 or SEQ ID No. 19.
2. The vaccine of claim 1, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.
3. A vaccine comprising a polypeptide encoded by a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
4. The vaccine of claim 3, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.
5. The vaccine of claim 3, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
6. The vaccine of claim 5, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No. 25.
7. The vaccine of claim 5, wherein the nucleotide sequence is SEQ ID No. 25.
8. The vaccine of claim 3, wherein the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No. 26.

9. The vaccine of claim 8, wherein the polypeptide has the amino acid sequence of SEQ ID No. 26.

10. The vaccine of claim 3, wherein the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No. 26.

11. The vaccine of claim 10, wherein the homologue has at least 80% sequence identity to SEQ ID No. 26.

12. The vaccine of claim 3, wherein the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32.

13. A vaccine comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

14. A vaccine according to claim 13, further comprising a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.

15. A vaccine comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

16. A vaccine comprising a pharmaceutically acceptable vehicle and a single polypeptide, wherein the single polypeptide consists of SEQ ID No. 26.